A Phase 1b Open-Label Three-Arm Multi-Center Study To Assess The Safety And Tolerability Of PF-05212384 (P13K/mTOR Inhibitor) In Combination With Other Anti-Tumor Agents
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Gedatolisib (Primary) ; Cisplatin; Dacomitinib; Docetaxel
- Indications Advanced breast cancer; Breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 17 Aug 2017 Planned End Date changed from 1 Dec 2019 to 18 Dec 2019.
- 17 Aug 2017 Planned primary completion date changed from 1 Dec 2019 to 18 Dec 2019.
- 24 Jul 2017 Planned End Date changed from 29 Nov 2019 to 1 Dec 2019.